KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study

被引：4

作者：

Chung, H. ^{[1
]}

Bang, Y. ^{[2
]}

Fuchs, C. ^{[3
]}

Qin, S. ^{[4
]}

Satoh, T. ^{[5
]}

Shitara, K. ^{[6
]}

Tabernero, J. ^{[7
,8
]}

Van Cutsem, E. ^{[9
,10
]}

Cao, Z. ^{[11
]}

Chen, X. ^{[11
]}

Kang, S. ^{[11
]}

Shih, C. ^{[11
]}

Janjigian, Y. ^{[12
]}

机构：

[1] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[2] Seoul Natl Univ, Coll Med, Seoul, South Korea

[3] Yale Canc Ctr, New Haven, CT USA

[4] Canc Ctr Peoples Liberat Army, Nanjing, Jiangsu, Peoples R China

[5] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan

[6] Natl Canc Ctr, Kashiwa, Chiba, Japan

[7] Vall dHebron Univ Hosp, Barcelona, Spain

[8] Inst Oncol VHIO, Barcelona, Spain

[9] Univ Hosp Gasthuisberg, Leuven, Belgium

[10] Katholieke Univ Leuven, Leuven, Belgium

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1093/annonc/mdz155.093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P 094

引用

页码：25 / 25

页数：1